3 British AI Stocks With Up To 14% Revenue Growth

Global markets are wrestling with a sharp bond sell off that has pushed UK long term borrowing costs above 6%, putting pressure on highly indebted sectors and rewarding companies that can cut waste and work smarter. That is exactly where artificial intelligence in healthcare comes in. In this article you will see three UK listed AI healthcare stocks from our screener that aim to turn this shift into potential long term value.

The three stocks highlighted below are just a starting sample from this theme, and the full screen surfaced 4 more UK listed healthcare AI companies with equally compelling stories that are not covered here. To identify your own highest conviction angles in this space, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener

Haleon (LSE:HLN)

Haleon is a consumer healthcare giant behind brands like Sensodyne, Panadol and Centrum. Its tie up with Microsoft puts AI tools directly into how those products are researched, made and delivered, which is where this theme starts to get interesting for long term investors.

Haleon generates about £4.7b from Europe, the Middle East, Africa and Latin America, £3.8b from North America and £2.6b from Asia Pacific, and the group is valued at roughly £29.7b, giving it meaningful scale to apply AI driven efficiencies across its operations.

"Artificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research."

The real question is what happens to Haleon’s margins if a single unseen pressure on those efficiency gains or product mix assumptions breaks.

If that question is on your mind, read the full narrative for Haleon to learn how Haleon’s AI push, brand power and cost pressures could be decoupling.

IXICO (AIM:IXI)

IXICO is a London based medical data specialist that runs AI enabled neuroimaging services for neurology clinical trials, using its IXICO platform to extract imaging biomarkers from brain scans. It generates about £7 million from medical labs and research work and has a market value of roughly £16 million.

IXICO plugs AI directly into MRI, PET and SPECT brain imaging for Alzheimer’s, Huntington’s, MS and Parkinson’s trials, turning complex scan data into biomarkers that drug developers can use. Interest in these AI powered reads is growing, although future demand and pricing depend on how one unseen pressure plays out.

That hinge point is exactly what you will see laid bare in the 1 key reward and 3 important warning signs (2 are major!), where IXICO’s AI opportunity sits beside the real pressure points.

AstraZeneca (LSE:AZN)

AstraZeneca leans into the AI healthcare theme through its oncology partnership with Tempus and PathOS, while its wider prescription drug portfolio still drives the financial story, with about US$61.4b from pharmaceuticals and a market value near £190.5b anchoring that effort.

"Ongoing investments in transformative technologies (such as next-generation ADCs, bispecific antibodies, mRNA platforms, and AI/digital-enabled clinical trial efficiencies) are expected to accelerate drug development cycles, enable precision medicine launches, and support higher net margins due to more efficient R&D and premium pricing potential."

The crux for investors is what happens to those margin ambitions if one key assumption inside this AI driven oncology push breaks.

If that breaking point matters to you, read the full narrative for AstraZeneca to understand how AstraZeneca’s AI oncology push could accelerate returns or expose hidden fault lines.

Seeking Alternatives Before The Crowd

Fresh ideas move first. By the time every screen lights up with the same tickers, the clean entry points can be gone. Scan these under the radar lists now and act early.

• Spot financially disciplined small caps before momentum screens catch them by running your eye over the curated 4 resilient stocks with low risk scores that focus on durability when markets turn.
• Review potential breakout themes in digital assets while they are still under the radar for now by checking the hand picked 19 cryptocurrency and blockchain stocks aligned with identified blockchain use cases.
• Identify income opportunities that seek to help portfolios address inflation risk by scanning the curated 1 dividend fortresses built around cash generation characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com